Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eOD-GT8 60mer mRNA vaccine
- Development stage
- Phase 1
- Lead developer
- International AIDS Vaccine Initiative
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
eOD-GT8 60mer mRNA vaccine is an experimental HIV vaccine candidate designed to prime the immune system to produce broadly neutralizing antibodies (bnAbs) against HIV. The vaccine encodes a germline-targeting immunogen (eOD-GT8 60mer) delivered via an mRNA platform. Its mechanism of action involves stimulating rare precursor B cells capable of developing into bnAb-producing cells, specifically those that can recognize conserved regions on the HIV envelope protein gp120. This priming step is intended as part of a multistep vaccination regimen to guide B cell maturation toward effective bnAb responses. The candidate is being developed through collaborations involving Scripps Research, IAVI Neutralizing Antibody Center, and Moderna, with support from the Bill & Melinda Gates Foundation and NIH agencies[2][5][6][8].
- Other names
- eOD-GT8 60-mereOD-GT-8 60-mereOD-GT 8 60-mereOD-GT8 60mer HIV vaccineeOD-GT-8 60mer HIV vaccineeOD-GT 8 60mer HIV vaccine
02
Targets
VRC01-class gl-BCR (VRC01-class germline B-cell receptor precursor)
Beyond the preview
Go deeper on eOD-GT8 60mer mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eOD-GT8 60mer mRNA vaccine.